NCT07114224

Aβ PET and Tau PET Imaging in the Diagnosis and Progression Assessment of Alzheimer's Disease

• Status: Not Yet Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 70 (estimated)
• Sponsor: Xijing Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

This prospective study recruited 20 healthy volunteers and 50 patients diagnosed with Alzheimer's disease (AD) and mild cognitive impairment (MCI) according to clinical guidelines. Participants underwent AV45/AV-1 and AV1451 PET imaging to obtain information on Aβ protein deposition, tau protein distribution, and structural and functional information. The study aims to evaluate the value of multimodal imaging features in the diagnosis and progression assessment of AD, providing imaging evidence for novel treatment modalities such as lecanemab therapy and deep cervical vein-lymphatic anastomosis.

Conditions

• Alzheimer Disease (AD)
• Cognitive Dysfunction, Cognitive Disorder
• PET Imaging

Interventions

Type	Name	Description
DIAGNOSTIC_TEST	AV45/AV-1、AV1451 PET	Use PET equipment to collect multimodal imaging data. Sixty to ninety minutes after intravenous injection of 3.7 MBq/kg of 18F-AV45 or 18F-AV1, perform PET imaging in list mode to simultaneously collect structural and functional information under the same pathophysiological conditions. The next day, perform 18F-AV1451 PET imaging to obtain tau protein distribution information.

Timeline

• Start date: 2025-08-15
• Primary completion: 2027-06-01
• Completion: 2027-06-01
• First posted: 2025-08-11
• Last updated: 2025-08-11